ROCR Value Based Program Act
- Sponsor
- Sen. Tillis, Thomas [R-NC]
- Committees
- Finance Committee (primary)
- Last action
- Mar 13, 2025
Bottom line
This bill fundamentally reforms how Medicare pays for radiation oncology by shifting to bundled payments, incentivizing patient-centered care and quality, while also addressing patient access through transportation support and protecting payment rates from broader budget cuts.
What it actually does
This bill establishes a new Medicare value-based payment program for radiation oncology services, transitioning from fee-for-service to per-episode case rate payments for specific cancer types. It aims to stabilize payments, reduce disparities, enhance quality, encourage technology use, and achieve cost savings. Additionally, the bill creates a new exception to civil monetary penalties for providers offering free or discounted transportation to radiation oncology patients and exempts the program's savings from broader Medicare budget neutrality adjustments.
Proponents argue
Proponents argue that the current Medicare payment system for radiation oncology is unstable, inadequately values professional expertise, and incentivizes volume over value. They contend this bill creates a stable, unified, and patient-centered payment model that rewards quality, encourages efficient care, and leverages technology, while also addressing health equity by supporting transportation for vulnerable patients. They emphasize the need for predictable payments to ensure access to high-quality care, especially in underserved areas.
Opponents contend
While direct opposition is not explicitly stated in the bill's findings, potential critics might argue that bundled payments, even with safeguards, could lead to under-provision of care or limit patient choice if providers are incentivized to shorten courses of treatment for financial reasons. Concerns might also be raised about the complexity of implementation for providers, especially smaller practices, despite exemptions for limited resource providers. Some might also question the long-term impact on innovation if new technologies are excluded from base rates for an extended period.
The bill is moderately complex, requiring careful reading to understand the intricate payment mechanisms and adjustments.
Section 3, adding new Section 1899C(a) to Title XVIII of the Social Security Act.
Creation of Radiation Oncology Case Rate Value Based Payment Program (ROCR Program)
This provision mandates the Secretary of Health and Human Services to establish a new payment program within one year. This program will pay radiation therapy providers and suppliers a single, bundled payment per episode of care for specific cancer treatments, moving away from the current fee-for-service model. It sets goals for the program, including payment stability, reducing disparities, enhancing quality, encouraging technology, and achieving cost reductions.
Supporters argue
Supporters argue this program will create stable, unified payments, reduce disparities by increasing access, enhance quality through accreditation and appropriate shorter courses of treatment, and protect Medicare resources by achieving reasonable spending reductions, addressing long-standing issues with current payment systems.
Critics contend
Potential critics might express concern about the administrative burden on providers to adapt to a new payment model and the risk of unintended consequences if the per-episode payments are set too low, potentially jeopardizing access or quality of care.
Tradeoffs
Balances the desire for cost containment and value-based care against potential risks to provider financial stability and patient access during a transition.
Section 3, new Section 1899C(b)
Structure and Timing of Per Episode Payments
This section details how the bundled payments will work. Providers will receive 80% of a determined per-episode payment amount, subject to deductibles and coinsurance. Payments are split, with half paid prospectively after the first treatment delivery and the remaining half at the end of the scheduled treatment or after 90 days (or 30 days for bone/brain metastases). Importantly, the payment amount will not vary based on whether the service is provided in a hospital outpatient department or a physician's office.
Section 3, new Section 1899C(d)
Establishing and Updating National Base Rates for Payments
This provision outlines how the base payment amounts for each cancer type will be calculated, starting from existing M-Code national base rates from 2021. It mandates annual updates based on economic indices (Medicare Economic Index for professional component, Hospital Inpatient Market Basket Update for technical component) with a payment floor. It also requires periodic rebasing every five years, with a limit of a 1% reduction per rebasing cycle, and includes specific rules for incorporating new technologies after a 12-year exclusion period.
Section 3, new Section 1899C(g)
Transportation Insecurity Add-On Payment
This section establishes an add-on payment to the per-episode amount for providers who identify patients experiencing "transportation insecurity" (ICD-10 diagnosis code Z59.82). The payment starts at $500 per patient per episode of care and increases by $10 annually. This payment is specifically for transportation services (excluding air, luxury, or ambulance) to help patients access and complete their radiation therapy treatments. Providers must document how these funds are spent.
Section 3, new Section 1899C(h)
Quality Incentives through Accreditation and EHR Requirements
This section introduces financial incentives for quality. For the first two years, accredited providers (or those in the process of accreditation) receive a 1% payment increase (0.25% for limited resource providers). After two years, non-accredited providers face a 2.5% payment reduction, while limited resource providers are exempt from this reduction. Accreditation must be from recognized organizations (ACR, ACRO, ASTRO) and providers must comply with certified EHR technology requirements.
Section 5, amending Sections 1833(t) and 1848(c)(2)(B) of the Social Security Act.
Budget Neutrality Exemption for ROCR Program
This crucial provision explicitly states that any reduced expenditures resulting from the implementation of the ROCR Program will not be taken into account when making budget neutrality adjustments for other Medicare payment systems (specifically the hospital outpatient prospective payment system and the physician fee schedule). This means that savings generated by the ROCR Program will not be used to offset increases or prevent cuts in other areas of Medicare spending.
Excludes new radiation therapy technologies or services from being incorporated into the national base rates for 12 years after their identification. During this period, they are paid under existing applicable payment systems.
Section 3, new Section 1899C(d)(2)(D)(i)(I)
Why it matters:This is standard legislative practice for managing the integration of new technologies into bundled payment models, allowing time for evaluation and market penetration. However, the 12-year period is quite long and could be contentious.
Case for: Supporters argue this allows for sufficient data collection on efficacy, cost-effectiveness, and market adoption before bundling, preventing the program from being burdened by unproven or excessively expensive early-stage technologies. It also provides a separate payment pathway during this period.
Case against: Critics might contend that a 12-year exclusion period could significantly delay patient access to cutting-edge treatments under the ROCR program and disincentivize innovation in radiation oncology, as manufacturers might face a prolonged period of uncertain payment integration.
Estimated impact: Potentially significant for both technology developers and patients seeking advanced treatments, affecting the pace of innovation adoption within the ROCR framework.
Defines "limited resource radiation therapy provider" and "supplier" based on criteria like patient volume/socioeconomic status, geographic area (including rural/medically-underserved), and other Secretary-determined factors. Crucially, it caps the total number of such providers/suppliers at 10% of all radiation therapy providers/suppliers.
Section 3, new Section 1899C(h)(1)(C)
Why it matters:While a definition, the 10% cap is a significant policy choice that could limit the reach of exemptions for smaller or rural practices, potentially impacting access.
Case for: Proponents argue the cap ensures that the quality incentive program remains broadly applicable while providing necessary flexibility for a small subset of truly disadvantaged providers, preventing widespread opt-outs that could undermine the program's quality goals.
Case against: Critics might argue that a fixed 10% cap is arbitrary and may not accurately reflect the actual number of providers facing significant resource limitations, potentially leaving many deserving practices without the necessary exemptions and risking their participation or viability.
Estimated impact: Could significantly influence the financial viability and participation of smaller or rural radiation therapy practices in the ROCR program, and thus patient access in those areas.
Specifies that the health equity add-on payment is made when the ICD-10 diagnosis code Z59.82, "transportation insecurity," is reported. It outlines a specific two-question screening process for providers to determine if this code should be reported.
Section 3, new Section 1899C(g)(2)(A) and (B)
Why it matters:This is a technical detail about coding, but it represents a significant policy decision to formally recognize and code a social determinant of health within the Medicare payment system, directly linking it to an additional payment.
Case for: Supporters argue that using a standardized ICD-10 code for transportation insecurity provides a clear, objective mechanism for identifying eligible patients and ensures that the add-on payment is directed to those most in need, while also generating valuable data on health disparities.
Case against: Critics might raise concerns about the potential for "upcoding" or inaccurate reporting of this diagnosis code to receive the additional payment, necessitating robust auditing and oversight. The two-question screening process, while simple, might still be seen as an additional administrative burden.
Estimated impact: Could lead to a significant increase in the reporting of social determinants of health and direct financial support for patient transportation, potentially improving treatment adherence.